scholarly journals Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions

Medicina ◽  
2021 ◽  
Vol 57 (11) ◽  
pp. 1246
Author(s):  
Hao-Wen Chuang ◽  
Jyh-Seng Wang ◽  
Jen-Wei Tsai ◽  
Chao-Tien Hsu ◽  
Kai-Jen Lin
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
High Specificity ◽  
Thyroid Neoplasms ◽  
Diagnostic Value ◽  
Papillary Thyroid ◽  
Close Relationship ◽  
Galectin 3 ◽  
Nuclear Features ◽  
Ihc Markers

Background and Objectives: We aimed to assess the diagnostic value of various immunohistochemical (IHC) markers and panels for differentiation among benign follicular nodules (BFNs), noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs), noninvasive encapsulated follicular variants of papillary thyroid carcinoma (NEFVPTCs), and infiltrative FVPTC (IFVPTC). Materials and Methods: Sixty-three cases were classified as BFNs, NIFTPs, NEFVPTCs, or IFVPTCs and were evaluated using the following markers: CK19, CD56, galectin-3, CITED1, HBME-1, VE1, and TROP-2. Results: The IHC results for NIFTP and NEFVPTC exhibited no statistically significant differences. In differentiating IFVPTCs from BFNs and NIFTPs/NEFVPTCs, galectin-3 and TROP-2 were the markers with the highest sensitivity plus high specificity, respectively. In various combinations, panel co-expression of two markers, including galectin-3 and/or HBME-1 and/or TROP-2, and the combination of galectin-3 and TROP-2 co-expression could achieve 100% in all aspects. In terms of discrimination of BFNs from NIFTP/NEFVPTC, CK19 was the single most sensitive marker (81.3%), while CD56 was the most specific (100%). The panel consisting of CK19 and/or HBME-1 exhibited the greatest sensitivity (96.9%), but the panel with CD56 and/or HBME-1 exhibited the greatest specificity (90.5%). Conclusions: Our results broaden the use of IHC markers for differential diagnoses among the four groups of follicular-based lesions. In addition, the similar IHC profiles of NIFTP and NEFVPTC also suggest the original criterion of <1% papillae within tumors, providing a reliable NIFTP diagnosis. Their close relationship may represent a spectrum of progressing neoplasia.

scholarly journals Serum Galectin-3: diagnostic value for papillary thyroid carcinoma

2015 ◽  
Vol 31 (4) ◽  
pp. 192-196 ◽  
Author(s):  
Erdem Yilmaz ◽  
Tamer Karsidag ◽  
Cihad Tatar ◽  
Sefa Tuzun
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Diagnostic Value ◽  
Papillary Thyroid ◽  
Galectin 3

HBME1 and CK19 in Non-Invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) vs Other Follicular Patterned Thyroid Lesions.

2021 ◽  
Author(s):  
Qandeel Sadiq ◽  
Radhika Sekhri ◽  
Daniel Dibaba ◽  
Qi Zhao ◽  
Shweta Agarwal
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Follicular Adenoma ◽  
Thyroid Neoplasms ◽  
University Hospital ◽  
Thyroid Neoplasm ◽  
Papillary Thyroid ◽  
Non Invasive ◽  
Significant Difference ◽  
Nuclear Features

Abstract Background: Thyroid neoplasms with follicular architecture can have overlapping morphologic features and pose diagnostic confusion amongst pathologists. Various immunohistochemical stains have been investigated as potential diagnostic markers for PTC; amongst which HBME1 and CK19 have gained popularity. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) poses similar diagnostic challenges with interobserver variability and is often misdiagnosed as adenomatoid nodule or follicular adenoma. This study aims to evaluate expression of HBME1 and CK19 in NIFTPs in comparison to other well differentiated thyroid neoplasms and benign mimickers. Method: 73 thyroid cases diagnosed over a period of 3 years at Methodist University Hospital, Memphis, TN were included in this study: 9 NIFTP, 18 papillary thyroid carcinoma (PTC), 11 follicular variant of papillary thyroid carcinoma, invasive (I-FVPTC), 24 follicular adenomas (FA), and 11 multinodular goiters/ adenomatoid nodules (MNG). A tissue microarray (TMA) was constructed and HBME1 and CK19 IHC was performed.Results: HBME1 was expressed in 77.8% NIFTPs, 88.9% PTC, 81.8% I-FVPTC, 16.7 % FA, and 18.2% MNGs. CK19 expression was seen in 66.7% NIFTPs, 83.3% PTC, 81.8% I-FVPTC, 33.3% FA and 45.4% MNGs. Difference in expression of HBME1 and CK19 was statistically significant for NIFTP vs FA (qualitative; p<0.05) and NIFTP vs MNG (p<0.05). No statistically significant difference was found for HBME1 in NIFTP vs PTC (conventional and FVPTC), p>/= 0.2. Sensitivity of HBME1 and CK19 for NIFTP were 78% and 67%, ~88% each for PTC, and 89% and 100% for FVPTC respectively, while specificity of HBME1 and CK19 for NIFTP were 53% each, ~62% each for PTC and ~55% each for FVPTC. Conclusion: Our study indicated that HBME1 and CK19 are valuable markers in differentiating NIFTPs from morphologic mimics like follicular adenoma and adenomatoid nodules/ multinodular goiter. While HBME1 and CK19 are both sensitive in diagnosing lesions with PTC like nuclear features, CK19 stains a higher number of benign lesions in comparison to HBME1. No increase in sensitivity or specificity in diagnosis of NIFTP, PTC or FVPTC was noted on combining the two antibodies.

scholarly journals Diagnostic Value of Serum lncRNA HOTAIR Combined with Galectin-3 in Benign and Papillary Thyroid Carcinoma

2021 ◽  
Vol Volume 13 ◽  
pp. 6517-6525
Author(s):  
Li Li ◽  
Jianjun Wang ◽  
Zhongquan Li ◽  
Shuang Qiu ◽  
Junyu Cao ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Diagnostic Value ◽  
Papillary Thyroid ◽  
Galectin 3 ◽  
Lncrna Hotair

scholarly journals Histomorphological study of malignant thyroid neoplasm in a tertiary care center and evaluation of Galectin 3 expression in papillary thyroid carcinoma

2020 ◽  
Vol 11 (SPL2) ◽  
pp. 220-227
Author(s):  
Nithin Diwagar K ◽  
Sridevi M ◽  
Chitra S
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumour Progression ◽  
Care Center ◽  
Tertiary Care ◽  
False Negative ◽  
Thyroid Neoplasms ◽  
Anaplastic Carcinoma ◽  
Papillary Thyroid ◽  
Galectin 3

Galectin-3 is a beta-galactoside binding animal lectin, which is frequently associated with tumour progression and metastasis. In recent years, overexpression of Galectin-3 has been reported in various human cancers and more frequently in thyroid neoplasms. The aim of this study was to analyze the histomorphological characteristics of malignant thyroid neoplasms, subtype them according to the established classification system and to evaluate the expression of Galectin-3 immunostaining in papillary thyroid carcinoma. A total of 30 cases were included in the study, out of which 28 cases were papillary thyroid carcinoma and its variants and one case of medullary and anaplastic carcinoma. Majority of the papillary thyroid carcinoma cases were positive for Galectin 3 immunostaining (25/28 cases – 89%) in our study. We conclude that galectin-3 is consistently expressed in papillary carcinoma thyroid; however, there are few false-negative cases in this study and also other studies have reported Galectin 3 overexpression in non-papillary tumors. Hence, we cannot depend on Galectin 3 expression alone as a single diagnostic tool to detect papillary thyroid carcinoma.

scholarly journals Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms – A Study from Kalaburagi, Karnataka

2021 ◽  
Vol 8 (26) ◽  
pp. 2288-2293
Author(s):  
Anuradha G. Patil ◽  
Saniya Jahan ◽  
Syed Mukhtar Mohiuddin
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Follicular Carcinoma ◽  
Thyroid Neoplasms ◽  
Malignant Neoplasms ◽  
Benign Neoplasms ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Galectin 3 ◽  
Malignant Thyroid Neoplasms

BACKGROUND Thyroid carcinoma is the most common endocrine malignancy. Galectin-3 has been implicated in malignant transformation and metastasis of cancer cells and it has received notable recognition for its usefulness as a diagnostic marker for thyroid cancer. We wanted to evaluate the expression of Galectin-3 on thyroid neoplasms, establish its diagnostic accuracy and also differentiate between benign and malignant thyroid lesions. METHODS A total of 54 thyroidectomy specimens were studied over a period of 3 years (2016 - 2019) which included 20 benign and 34 malignant thyroid neoplasms. Histopathologic evaluation of H & E stained sections was done and immunohistochemistry (IHC) staining for Galectin-3 was performed for all neoplasms with the polymeric method using lyophilized mouse monoclonal antibody. (Path n Situ) and grading based on intensity of Galectin-3 expression were noted. RESULTS Galectin-3 expression was significantly higher (P < 0.001) in malignant thyroid neoplasms in comparison to the benign neoplasms. Galectin-3 expression for malignant neoplasms showed sensitivity of 88.23 %, specificity of 95.0 %, positive predictive value (PPV) of 96.8 % and negative predictive value (NPV) of 82.6 %. Galectin-3 expression in Papillary thyroid carcinoma showed a sensitivity of 95.83 % and PPV of 88.2 %. While comparing the neoplasms showing follicular pattern, Galectin-3 expression was more in the malignant neoplasms (follicular carcinoma and follicular variant of papillary carcinoma thyroid) than benign neoplasms (follicular adenoma). CONCLUSIONS Galectin-3 is a useful marker in differentiating benign and malignant thyroid neoplasms. Galectin-3 is sensitive for Papillary thyroid carcinoma (PTC) and among the follicular patterned lesions, Galectin-3 is sensitive for follicular variant of papillary carcinoma and follicular carcinoma. Thus Galectin-3 protein expression evaluated using immunohistochemistry technique acts as an adjunctive ancillary technique in thyroid cancer diagnosis. KEYWORDS Galectin-3, Immunohistochemistry, Thyroid Carcinoma, Papillary Thyroid Carcinoma

Utility of Tumor Capsule Thickness as a Predictor of Invasion in Encapsulated Follicular Variant of Papillary Thyroid Carcinoma and a Diagnostic Tool for Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features

2019 ◽  
Vol 28 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Brenda French ◽  
Georgette Hattier ◽  
Stacey K. Mardekian
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Predictive Marker ◽  
Thyroid Neoplasms ◽  
Thyroid Neoplasm ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Tumor Capsule ◽  
Capsule Thickness ◽  
Nuclear Features

Context. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an extremely indolent subset of noninvasive encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC). These lesions share certain features including a delimiting fibrous capsule, and they are distinguished by detailed histological criteria. Objective. We sought to identify whether tumor capsule thickness differs significantly between NIFTP and noninvasive EFVPTC lesions. We also compared tumor capsule thickness between noninvasive and invasive EFVPTC in order to evaluate its utility as a predictive marker of invasion. Design. Encapsulated follicular thyroid neoplasms with papillary-like nuclear features diagnosed over a 3-year period at a single institution were subcategorized into NIFTP, noninvasive EFVPTC, and invasive EFVPTC based on current diagnostic criteria. Maximum tumor capsule thickness for each lesion was measured. Results. A total of 92 lesions (39 NIFTP, 15 noninvasive EFVPTC, and 38 invasive EFVPTC) were evaluated. Tumor capsule thickness was significantly thinner in NIFTP ( P = .022) and significantly thicker in invasive EFVPTC ( P = .0006) when compared with noninvasive EFVPTC. Conclusions. Tumor capsule thickness may be an additional useful marker when distinguishing between NIFTP and noninvasive EFVPTC. A capsule thickness of greater than 0.2 mm should raise suspicion for EFVPTC and thus prompt more thorough review of the submitted tissue for NIFTP exclusionary criteria. Additionally, if capsular and/or vascular invasion are not present on initial slides of an entirely evaluated capsule of EFVPTC that exceeds 0.5 mm in thickness, the pathologist should order additional tissue levels to ensure that a small focus of invasion is not missed.

Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features

Thyroid ◽  
2018 ◽  
Vol 28 (3) ◽  
pp. 319-327 ◽  
Author(s):  
Iman Jahanbani ◽  
Abeer Al-Abdallah ◽  
Rola H. Ali ◽  
Nabeel Al-Brahim ◽  
Olusegun Mojiminiyi
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Neoplasms ◽  
Papillary Thyroid ◽  
Nuclear Features

scholarly journals HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Qandeel Sadiq ◽  
Radhika Sekhri ◽  
Daniel T. Dibaba ◽  
Qi Zhao ◽  
Shweta Agarwal
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Follicular Adenoma ◽  
Thyroid Neoplasms ◽  
University Hospital ◽  
Thyroid Neoplasm ◽  
Papillary Thyroid ◽  
Non Invasive ◽  
Significant Difference ◽  
Nuclear Features

Abstract Background Thyroid neoplasms with follicular architecture can have overlapping morphologic features and pose diagnostic confusion among pathologists. Various immunohistochemical stains have been investigated as potential diagnostic markers for PTC, among which HBME1 and CK19 have gained popularity. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) poses similar diagnostic challenges with interobserver variability and is often misdiagnosed as adenomatoid nodule or follicular adenoma. This study aims to evaluate expression of HBME1 and CK19 in NIFTPs in comparison to other well-differentiated thyroid neoplasms and benign mimickers. Method Seventy-three thyroid cases diagnosed over a period of 3 years at Methodist University Hospital, Memphis, TN, USA, were included in this study: 9 NIFTP; 18 papillary thyroid carcinoma (PTC); 11 follicular variant of papillary thyroid carcinoma, invasive (I-FVPTC); 24 follicular adenomas (FA); and 11 multinodular goiters/adenomatoid nodules (MNG). A tissue microarray (TMA) was constructed and HBME1 and CK19 immunohistochemistry was performed. Results 77.8% of NIFTPs, 88.9% of PTCs, 81.8% of I-FVPTCs, 16.7% of FAs, and 18.2% of MNGs showed HBME-1 expression. 66.7% of NIFTPs, 83.3% of PTCs, 81.8% of I-FVPTCs, 33.3% of FAs, and 45.4% of MNGs expressed CK19. Difference in expression of HBME1 and CK19 was statistically significant for NIFTP vs FA (qualitative; p < 0.05) and NIFTP vs MNG (p < 0.05). No statistically significant difference was found for HBME1 in NIFTP vs PTC (conventional and FVPTC), p ≥ 0.2. Sensitivity of HBME1 and CK19 for NIFTP were 78% and 67%, ~ 88% each for PTC, and 89% and 100% for FVPTC, respectively, while specificity of HBME1 and CK19 for NIFTP were 53% each, ~ 62% each for PTC, and ~55% each for FVPTC. Conclusion Our study indicated that HBME1 and CK19 are valuable markers in differentiating NIFTPs from morphologic mimics like follicular adenoma and adenomatoid nodules/multinodular goiter. While HBME1 and CK19 are both sensitive in diagnosing lesions with PTC-like nuclear features, CK19 stains a higher number of benign lesions in comparison to HBME1. No increase in sensitivity or specificity in diagnosis of NIFTP, PTC, or FVPTC was noted on combining the two antibodies.

Sign in / Sign up

Export Citation Format

Share Document